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Kinases have been implicated in the immunopathological mechanisms of Systemic Lupus Erythematosus (SLE). v-akt murine-
thymoma viral-oncogene-homolog 1 (AKT1) and mitogen-activated-protein-kinase 1 (MAPK1) gene expressions in peripheral
mononuclear cells from thirteen SLE patients with inactive or mild disease were evaluated using quantitative real-time reverse-
transcription polymerase-chain-reaction and analyzed whether there was any correlation with T-helper (Th) transcription factors
(TF) gene expression, cytokines, and S100A8/S100A9-(Calprotectin). Age- and gender-matched thirteen healthy controls were
examined. AKT1 and MAPK1 expressions were upregulated in SLE patients and correlated with Th17-(Retinoic acid-related
orphan receptor (ROR)-C), T-regulatory-(Treg)-(Transforming Growth Factor Beta (TGFB)-2), and Th2-(interleukin (IL)-
5)-related genes. MAPK1 expression correlated with Th1-(IL-12A, T-box TF-(T-bet)), Th2-(GATA binding protein-(GATA)-
3), and IL-10 expressions. IL-10 expression was increased and correlated with plasma Tumor Necrosis Factor (TNF)-α and
Th0-(IL-2), Th1-(IL-12A, T-bet), GATA3, Treg-(Forkhead/winged-helix transcription factor- (FOXP)-3), and IL-6 expressions.
FOXP3 expression, FOXP3/RORC, and FOXP3/GATA3 expression ratios were increased. Plasma IL-1β, IL-12(p70), Interferon-
(IFN)-γ, and IL-6 cytokines were augmented. Plasma IL-1β, IL-6, IL-2, IFN-γ, TNF-α, IL-10, and IL-13 correlated with C-
reactive protein, respectively. Increased Calprotectin correlated with neutrophils. Conclusion, SLE patients presented a systemic
immunoinflammatory activity, augmented AKT1 andMAPK1 expressions, proinflammatory cytokines, and Calprotectin, together
with increased expression of Treg-related genes, suggesting a regulatory feedback opposing the inflammatory activity.
1. Introduction
Systemic Lupus Erythematosus (SLE) is a chronic inflam-
matory autoimmune disease most common in women of
reproductive age [1], characterized by a relapsing/remitting
course and the involvement of multiple organs, including
skin, kidneys, and central nervous system. Pathophysio-
logically is characterized by the dysfunction of T, B, and
dendritic cells (DC), skewed cytokine production, break-
down of immunological tolerance, and by the production of
antinuclear autoantibodies [2–5].
In SLE bone marrow mononuclear cells, Nakou et al.
[6] identified central gene regulators implicated in disease
pathogenesis which include activation of multiple kinase
pathways (MAPK/extracellular regulatedMAP kinase (ERK),
Signal Transducer and Activator of Transcription (STAT),
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AKT, and PI3-kinase (PI3 K)). AKT1 serine/threonine kinase
is a key downstream target of PI3 K signaling pathway, and
plays a role in the diﬀerentiation of peripheral B cells and in T
cell homeostasis [7–10]. Upregulated activity of AKT kinases
has been documented in B cells from SLE patients [11].
AKT/Mammalian target of rapamycin (mTOR) axis has been
successfully targeted with rapamycin for treatment of SLE
patients [2]. MAPK/ERK kinases play a significant role in
immune-mediated inflammatory responses and are involved
in the maintenance of T-cell tolerance that fails in SLE
patients [4, 12]. Molad et al. [13] reported increased ERK
and JNK activities that correlated with disease activity in SLE
patients. Conversely, other studies documented a reduced
MAPK activity in human SLE T cells [4]. In mice, a defect in
lupus T cell ERK pathway signaling that can cause epigenetic
abnormalities in T cells by inhibiting DNA methylation has
been reported [12, 14]. In addition, in SLE T cells, alterations
in kinases pathways such as the spleen tyrosine kinase (Syk)
signaling patterns have been documented by Krishnan et al.
[15].
The imbalance in cytokine activities is associated with
human autoimmune and autoinflammatory diseases, and it
has been reported to play a central role in regulating SLE
development [16–20]. There is a key collaboration and reg-
ulation between key cytokines in activation/induction of
transcription factors during the process of T-helper-(Th)-
cell diﬀerentiation towards Th1, Th2, Th17, and induced
regulatory T (iTreg) cells lineages [21, 22]. Changes in Th-
specific transcription factors gene expression ratios have
been used as a marker of Th-cytokine balance [20, 23–26].
Moreover, increased inflammation mediators S100A8/
S100A9-(Calprotectin) serum and/or plasma levels have
been reported in SLE patients [27–29]. Damage-associated
molecular pattern molecules (DAMP) S100A8 and S100A9
members of the calcium-binding S100-family make a het-
erotetrameric form, S100A8/S100A9-(Calprotectin).
The aim of this study is to assess the gene expres-
sion levels of intracellular kinases AKT1 and MAPK1 in
peripheral blood mononuclear cells (PBMC) from SLE
patients with inactive or mild disease and to analyze whether
there was any correlation with Th-transcription factors
gene expression, with gene expression and plasma levels
of a comprehensive panel of cytokines (Th0-, Th1/Th17-,
and Th2/Treg-type), with plasma inflammation mediators
S100A8/A9-Calprotectin and clinical parameters.
2. Materials andMethods
2.1. Patients and Controls. The study protocol was approved
by the SCUH Committee and CSIC Review Board and
Ethics Committees. Written informed consent was obtained
from all participating patients and controls, according to the
Helsinki Declaration. Clinical data and treatments of patients
are summarized (Table 1). Thirteen SLE outpatients (eleven
women and two men) with inactive or mild disease (SLE
disease activity index (SLEDAI) score ≤ 4) (0 (0–3) (median
(25% and 75% percentile ranges), see Table 1) that fulfilled
at least four of the revised SLE criteria of the American
College of Rheumatology (ACR) for the diagnosis of SLE
[30, 31] were evaluated. Age- and gender-matched healthy
controls (C) included thirteen volunteers subjects, without
known autoimmune disease (eight women and five men;
34 (30–51.5) years old; diﬀerences versus SLE patients were
not statistically significant, Mann-Whitney, P = 0.1435).
Likewise, no significant diﬀerences in gender distribution
were observed between patients and controls (Fisher test:
P = 0.3783, for SLE patients versus C). Patients and controls
were Caucasians.
Medications taken by the patients at the time the blood
was drawn were recorded (Table 1). The majority of SLE
patients (n = 12) were treated with hydroxychloroquine
(200mg/day); nine SLE patients were also treated with pred-
nisone (5mg/day), and six of them were additionally treated
with one of methotrexate, azathioprine, or mycophenolate
mofetil (Table 1).
2.2. Blood, Plasma, and PBMC Samples. Blood was collected
(BD Vacutainer system, K2-EDTA tubes, BD Diagnostics,
Franklin Lakes, NJ, USA) and plasma and PBMC were
separated using density gradient centrifugation [24].
2.3. RNA Isolation and Quantitative Real-Time Reverse
Transcription-Polymerase Chain Reaction (qRT-PCR). Gene
expression levels were measured quantitatively by qRT-PCR
as previously described [24]. Total RNA was isolated from
PBMC from thirteen SLE patients, and four controls, using
RNeasy Plus mini kit (Qiagen, Hilden, Germany). RNA qual-
ity was assessed by an Experion Automated Electrophore-
sis Station (Bio-Rad, Hercules, CA, USA). RT reaction,
primer sequences, and gene-specific primers used in this
studio are indicated (Table 2 and Supplementary Materials).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as an endogenous control. To quantify cytokine mRNA
expression, a RT2 Profiler PCR Array System (SABiosciences,
Qiagen) was used. The PCR Array layout contained gene-
specific primers for ten cytokines: Interleukin (IL)-1B, IL-
2, IL-5, IL-6, IL-10, IL-12A, Tumor Necrosis Factor (TNF)-
α, Interferon (IFN)-γ, Transforming Growth Factor Beta
(TGFB)-2, and Tumor Necrosis Factor-Related Apoptosis-
Inducing Ligand or TRAIL (TNFSF)-10; two internal loading
gene-specific primers controls were included for standard-
ization between samples (GAPDH and β-actin, Table 2).
Proportion of transcript present in the samples was calcu-
lated using the relative quantification 2−ΔΔCt scheme [32].
Control samples were used as comparative calibrator. Results
represented the relative amount of amplicon in patient’s
sample (fold change) to the mean level of the transcripts in
the control samples.
2.4. Plasma Cytokines. Bio-Plex Precision Pro Human
Cytokine 10-Plex kit assays were used to simultaneously test
10 cytokines in plasma: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-
10, IL-12(p70), IL-13, IFN-γ, and TNF-α, in according with
manufacturer’s protocol (Bio-Rad).
2.5. Human S100A8/S100A9 Heterodimer Complexes or Cal-
protectin Enzyme Linked Immunosorbent Assay (ELISA).
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Table 2: Primers for quantitative RT-PCR.
Gene1 Accession no.1 Description SABiosciences Cat. no.2
IL-1B NM 000576 Interleukin 1, beta PPH00171B
IFNG NM 000619 Interferon, gamma PPH00380B
IL-12A NM 000882 Interleukin 12A PPH00544B
IL-6 NM 000600 Interleukin 6 PPH00560B
TNF-alpha NM 000594 Tumor necrosis factor (TNF superfamily, member 2) PPH00341E
IL-10 NM 000572 Interleukin 10 PPH00572B
IL-2 NM 000586 Interleukin 2 PPH00172B
TGFB2 NM 003238 Transforming growth factor, beta 2 PPH00524B
IL-5 NM 000879 Interleukin 5 PPH00692A
TNFSF10 NM 003810 Tumor necrosis factor (ligand) superfamily, member 10 PPH00242E
GAPDH NM 002046 Glyceraldehyde-3-phosphate dehydrogenase PPH00150E
ACTB NM 001101 Actin, beta PPH00073E
TBX21 NM 013351 T-box-21 (T-bet) PPH00396A
GATA3 NM 002051 GATA-binding protein 3 PPH02143A
FOXP3 NM 014009 Forkhead box P3 PPH00029B
STAT4 NM 003151 Signal transducer and activator of transcription 4 PPH00777E
RORC NM 005060 RAR-related orphan receptor C PPH05877A
MAPK1 NM 002745 Mitogen-activated-protein-kinase 1 PPH00715B
AKT1 NM 005163 v-akt murine-thymoma viral-oncogene-homolog 1 PPH00088A
CD38 NM 001775 CD38 molecule PPH00856A
ZAP70 NM 001079 Zeta-chain (TCR) associated protein kinase 70 kDa PPH00256A
CD247 NM 000734 CD247 molecule, CD3-zeta. PPH01484A
CCR6 NM 004367 Chemokine (C-C motif) receptor 6 PPH00616E
Gene1,3 Forward primer (5′–3′)4 Reverse Primer (5′–3′)4 Ref.
GAPDH (NM 002046) gaaggtgaaggtcggagtc gaagatggtgatgggatttc Primer3 software3
1
http://www.ncbi.nlm.nih.gov/.
2SABiosciences, QIAGEN company.
3http://frodo.wi.mit.edu/primer3/.
4Primers used for this study based on the literature were computationally checked for sequence specificity. Melt-curve analysis for each primer pair and
reaction was also tested to verified specific amplification.
Plasma concentration, a noncovalently associated Calprotec-
tion, in the presence of calcium, was measured in duplicate
using a sandwich ELISA kit (no. HK325; Hycult Biotechnol-
ogy, Uden, The Netherlands).
2.6. Statistics. Data are given as median and 25% and 75%
percentile ranges, or otherwise indicated. Relative mRNA
expression levels of the genes in patients’ PBMC versus
controls were evaluated using the nonparametric Wilcoxon
Signed Rank test and comparing the medians against a
hypothetical median (value equal 1). Determinations of sig-
nificant diﬀerences between groups were compared using the
non-parametric Mann-Whitney U test. Fisher exact test was
used for analysis of qualitative variables. Correlations were
determined by Spearman’s rank correlation test. Diﬀerences
were considered statistically significant for P values < 0.05
(GarphPad Prism v.5.01, GraphPad, CA, USA).
3. Results
3.1. Intracellular kinases and Immunoreceptors Gene Expres-
sions Levels. AKT1 (7.82 (2.61–11.45)), MAPK1 (19.47
(8.71–33.45)), and ZAP70 (1.98 (1.14–3.66)) relative gene
expressions levels were significantly augmented in PBMC
from SLE patients (n = 13) as compared with controls
(Wilcoxon Signed Rank test: P = 0.0064, P = 0.0012, and
P = 0.0024, resp.) (Figure 1(a)). CD38 (1.22 (0.77–1.95))
and CD3zeta (1.15 (0.54–1.83)) immunoreceptors relative
gene expression levels were also evaluated; not significantly
diﬀerences were observed versus controls (Wilcoxon Signed
Rank test: P = 0.0805, P = 0.7869, resp.) (Figure 1(a)).
In addition, the Th17-associated CC chemokine receptor
(CCR)-6 relative gene expression was significantly decreased
in SLE’s PBMC versus controls (0.50 (0.33–0.95), Wilcoxon
Signed Rank test, P = 0.0398) (Figure 1(a)).
3.2. Increased Treg/Th17 and Treg/Th2 Transcription Factors
Gene Expression Ratios. In PBMC from patients and con-
trols, relative gene expression of T-box transcription factor
(T-bet or TBX21) and signal transducer and activator of
transcription (STAT)-4, both for Th1 cells; GATA3, a
member of the GATA family of zinc finger proteins for
Th2; retinoic acid-related orphan receptor (ROR)-C, for
Th17 cells and forkhead/winged helix transcription factor
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Figure 1: (a) Intracellular kinases and immunoreceptors gene
expressions levels. RNAs extracted from PBMC of SLE patients (n =
13) and controls (n = 4) were reverse transcribed, and the gene
expression levels were determined by qRT-PCR using gene-specific
primers for indicated genes and GAPDH to normalize the mRNA
expression (Materials and Methods, Supplementary Materials, and
Table 2). Proportion of transcript present in the samples was
calculated using the relative quantification 2−ΔΔCt scheme. Control
samples were used as comparative calibrator. Final results represent
the relative amount of amplicon in patient’s sample (fold change)
to the mean level of the transcripts in the control samples. In the
figure, results are represented in box plots given the median
(horizontal bars within boxes), the mean (cross points); box
limits correspond to quartiles, and vertical lines indicate the 5–
95 percentile range. Results are represented in a log 10 scale, and
the indicated numbers are the antilog values. Significance levels set
at P values <0.05. AKT1, MAPK1, and ZAP70 gene expressions
were increased in SLE patients compared with controls (Wilcoxon
Signed Rank test: P = 0.0064, P = 0.0012, P = 0.0024). Gene
expression of CCR6 was decreased in SLE patients compared with
controls (Wilcoxon Signed Rank test: P = 0.0398). (b) T-helper
transcription factors gene expression ratios in SLE patients. Results
are expressed as indicated in (a). FOXP3/RORC ratio in SLE
patients versus controls (Wilcoxon Signed Rank test, P = 0.0042).
FOXP3/GATA3 ratio in SLE versus controls (Wilcoxon test, P =
0.0017).
Table 3: Cytokines relative mRNA levels in PBMC.
Genesa SLE (n = 13)b
IL-1B 1.36 (0.75–1.88)
IL-2 1.20 (0.26–6.03)
IL-5 1.41 (0.60–2.70)
IL-6 1.41 (0.58–6.08)
IL-10 1.98c(1.21–5.37)
IL-12A 1.67 (0.58–2.81)
IFN-γ 1.24 (0.74–2.32)
TNF-α 0.20 (0.16–2.20)
TGFB2 1.17 (0.25–2.24)
TNFSF10 1.37 (0.95–1.92)
a
RNAs extracted from PBMC of SLE patients (n = 13) and controls
(n = 4) were reverse transcribed, and the gene expression levels were
determined by qRT-PCR using gene-specific primers for indicated genes
to quantify cytokine mRNA expression, by means of a RT2 Profiler
PCR Array System (Table 2). qRT-PCR methods (Materials and Methods
and Supplementary material). Two internal loading gene-specific primers
controls were included for standardization between samples (GAPDH and
β-actin, Table 2). Proportion of transcript present in the samples was
calculated using the relative quantification 2−ΔΔCt scheme. Control samples
were used as comparative calibrator. Final results represent the relative
amount of amplicon in patient’s sample (fold change) to the mean level of
the transcripts in the control samples.
bValues of the relative mRNA levels are presented as Median (25th to 75th
percentile).
cIL-10 gene expression was increased in SLE patients compared with
controls (Wilcoxon Signed Rank test, P = 0.0046).
Analysis of the data was done using the GraphPad Prism v.5.01 software.
(FOXP)-3 for Treg cells [33, 34] were assessed and Th-
transcription factors gene expression ratios calculated.
FOXP3 relative gene expression was significantly increased in
SLE patients versus controls (18.3 (1.39–44.14), n = 13,
Wilcoxon test, P = 0.0012). However, there were no statis-
tically significant diﬀerences between medians of the T-bet
(5.94 (0.44–63.98)), STAT4 (1.09 (0.60–2.07)), RORC (4.49
(0.60–30.56)) and GATA3 (2.80 (0.79–8.19)) relative gene
expressions levels, respectively, versus controls (Wilcoxon
Signed Rank test, P = 0.0681; P = 0.3054, P = 0.0681,
P = 0.0574, for T-bet, STAT4, RORC, and GATA3, resp.).
In SLE patients, gene expression ratios of both FOXP3/
RORC (1.90 (1.41–4.85)) and FOXP3/GATA3 (2.17 (1.67–
7.22)) were significantly increased versus controls (Wilcoxon
Signed Rank test, P = 0.0042 and P = 0.0017, resp.)
(Figure 1(b)). While, ratios of T-bet/RORC (1.48 (1.09–
1.95)), T-bet/GATA3 (1.24 (0.64–6.77)), and RORC/GATA3
(1.25 (0.79–3.23)) were evaluated and no significantly diﬀer-
ences were observed between SLE versus controls (Wilcoxon
Signed Rank test, P = 0.0503, P = 0.1099, and P = 0.0942,
resp., Figure 1(b)).
3.3. Cytokines Gene Expression, Plasma Levels, and Correla-
tions. In SLE patients, cytokines mRNA expressions were
evaluated using a RT2 Profiler PCR Array System. Results
indicated that IL-10 relative gene expression was significantly
increased versus controls (Table 3). In addition, ten cytokines
were simultaneously assessed in each plasma sample using
a Bio-Plex (Table 4). Results indicated that plasma levels
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Table 4: Cytokines plasma levels.
Cytokinesa, b SLE (n = 13) Controls (n = 13) P valuec
IL-1β 0.24 (0.10–0.96) 0.10 (0.10–0.13) 0.0112
IL-2 0.61 (0.60–20.24) 0.60 (0.60–2.62) 0.1893
IL-4 0.10 (0.10–0.68) 0.10 (0.10–0.19) 0.6607
IL-5 1.00 (1.00–1.00) 0.90 (0.80–1.00) 0.0077
IL-6 1.00 (1.00–22.35) 1.00 (0.85–1.00) 0.0117
IL-10 2.82 (0.75–9.64) 0.63 (0.60–3.22) 0.1368
IL-12(p70) 1.02 (0.60–1.68) 0.18 (0.06–0.50) 0.0009
IL-13 0.20 (0.20–3.87) 0.20 (0.19–0.21) 0.0685
IFN-γ 0.64 (0.20–3.76) 0.20 (0.20–0.33) 0.0445
TNF-α 0.34 (0.10–2.10) 0.10 (0.10–0.30) 0.1193
a
A multiplex bead array (Bio-Plex, BioRad) was used to simultaneously
measure 10 diﬀerent cytokines in each plasma sample. Samples from
patients and controls were analyzed in parallel. Values are in pg/mL. Limits
of detection (pg/mL) for the indicated cytokines were: 0.1, 0.64, 0.17, 0.88,
0.29, 0.17, 0.37, 0.19, 0.35, and 0.2, respectively. Analyses of data were
performed using five-parameter logistic curve fitting to standard analyte
values. Intra-assay and interassay CV were ≤8% and ≤10%, respectively.
bValues are presented as Median (25th to 75th percentiles).
cMann-Whitney U test for comparison between SLE and controls.
Significance levels set at P values <0.05. The analysis of the data was done
using the GraphPad Prism v.5.01 software.
of proinflammatory cytokines IL-1β, IL-6 (both Th17), IL-
12(p70), IFN-γ (both Th1) together with IL-5 (Th2) were
significantly augmented in SLE patients versus controls
(Table 4).
In SLE (n = 13) patients, IL-1β and IL-6 plasma levels
were positively correlated to IL-1B and IL-6 gene expression
levels, respectively (Table 5). IL-6 gene expression also pos-
itively correlated with Th1 (IL-12(p70), IFN-γ, and TNF-
α), Th0 (IL-2), Th17 (IL-1β), and IL-10 plasma cytokines,
respectively. There was a positive correlation between IL-
10 gene expression and plasma TNF-α (Table 5). While
there was a negative correlation between IL-10 and TNF-α
gene expressions (r = −0.6905, P = 0.009). There were
significant positive correlations in the IL-2, IL-6, IL-10, IL-
12A, and TGFB2 gene expressions, which were correlated
to one another; except for IL-6 and TGFB2 (Table 5). In
addition, IFN-γ and IL-12A gene expressions were positively
correlated (Table 5).
3.4. AKT1, MAPK1, and Th-Transcription Factors Gene
Expressions Correlations. In SLE patients, there were signifi-
cant correlations between MAPK1, AKT1, T-bet, RORC, and
GATA3 relative gene expressions, respectively (Table 6).
Additionally, AKT1 gene expression was correlated to both
RORC (Table 6) and CD38 expressions (Table 8), respec-
tively. Moreover, there were significant correlations in the T-
bet, STAT4, GATA3, RORC, and FOXP3 gene expressions,
which were correlated to one another (Table 6). Both
AKT1 and MAPK1 gene expressions were correlated with
gene expression levels of Treg-(TGFB2) and Th2-(IL-5)
cytokine-related genes, respectively (Table 7). There was also
a correlation between AKT1 and TNFSF10 (TRAIL) gene
expressions (Table 7). Additionally, MAPK1 gene expression
was correlated to IL-10 and IL-12A gene expressions (Table
7). Furthermore, significant correlations between IL10 rel-
ative gene expression and FOXP3, RORC, GATA3, T-bet,
(Table 7), and CD38 gene expressions (Table 8), respectively,
were observed. Correlations between FOXP3 gene expression
and Th1 (IL-12A, IFN-γ), Th0 (IL-2), Treg-(TGFB2), Th2-
(IL-5), and IL-6 gene expressions, respectively, were observed
(Table 7).
3.5. Plasma S100A8/A9 Calprotectin, Clinical Parameters, and
Correlations. Plasma levels of inflammation mediator Cal-
protectin were augmented in SLE patients (175.6 (138.9–
229.2) ng/mL, n = 13), as compared with controls (143.3
(133.4–151.9) ng/mL, n = 11) although diﬀerences were
not statistical significant (Mann-Whitney, P = 0.0637). Our
data are consistent with previous reports [27–29, 35]. In
SLE patients, Calprotectin was correlated with neutrophils
numbers (Table 8). In addition, significant correlations were
obtained between disease-marker C-reactive protein (CRP)
and plasma cytokines type Th1-(IFN-γ, TNF-α), Th0-(IL-
2), Th2-(IL-13), Th17-(IL-1β, IL-6), and IL-10, respectively
(Table 8). Patients’ age was correlated with gene expression
levels of IL-2, IL-10, IL-12A, TGFB2, and GATA3 relative
gene expressions, respectively (Table 8). Moreover, in SLE
patients, C4-complement levels were correlated to CCR6
(lymphocyte traﬃcking) and STAT4 gene expressions levels,
respectively, which were correlated to one another (Table 8).
In mice, CCR6 was recently identified by Wei et al.
[36] among the STAT4-occupied genes. Lastly, lymphocytes
numbers negatively correlated with TNFSF10 (TRAIL) gene
expression (Table 8).
4. Discussion
In this study, we observed that AKT1 and MAPK1 gene
expressions were upregulated in SLE patients with mild or
inactive disease and correlate with gene expressions levels
of Th17-(RORC), Treg-(TGFB2), and Th2-(IL-5)-related
genes, respectively. Additionally, AKT1 gene expression
also correlates with MAPK1 expression in SLE patients.
PI3 K/AKT and MAPK pathways are regulated by extensive
crosstalk at diﬀerent levels [9, 37]. AKT eﬀect on the
generation and function of Treg and Th17 cells is not
well understood. Wan et al. [38] reported that RORC was
necessary, but not suﬃcient, for IL-17 production by human
memory T cells, and they proposed that RORC synergized
with common γ chain-cytokines mediated PI3 K and AKT
signaling to transactivate IL-17 expression. Recently, Kure-
bayashi et al. [39] demonstrated in mice that the suppression
of PI3 K-AKT-mammalian target of Rapamycin complex
(mTORC)-1 axis impaired Th17 diﬀerentiation in vitro
and in vivo in S6 kinases 1 and 2-dependent fashion. In
mice, Sauer et al. [40] documented that T cell receptor
(TCR) signaling via PI3Kp110α, p110δ, AKT, and mTOR
controls FOXP3 expression in activated CD4+ thymocytes
and peripheral T cells. PI3 K-AKT axis has also been reported
augments clonal expansion of Th1 and Th2 cells [41, 42].
In mature T cells, constitutively active AKT could induce
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Table 5: Spearman’s rank correlations obtained between cytokines gene expressions in PBMCs and cytokines plasma levels in SLE patients.
Gene
SLE (n = 13)
Plasma cytokines
IL-1β IL-2 IL-6 IL-10 IL-12(p70) IFN-γ TNF-α
IL-1B
r 0.6082
P 0.0274
IL-6
r 0.6110 0.7427 0.7204 0.8253 0.6877 0.7856 0.8970
P 0.0265 0.0036 0.0055 0.0005 0.0094 0.0015 <0.0001
IL-10
r 0.6101
P 0.0268
Gene
Gene
IL-2 IL-6 IL-10 IL-12A IFN-γ TGFB2
IL-2
r 1 0.6538 0.6319 0.9106 0.7868
P 0.0153 0.0205 <0.0001 0.0014
IL-6
r 1 0.7582 0.7180
P 0.0027 0.0057
IL-10
r 1 0.7813 0.6190
P 0.0016 0.0241
IL-12A
r 1 0.6905 0.7796
P 0.0090 0.0017
Significant Spearman’s rank correlations coeﬃcients are indicated.
Significance levels set at P values <0.05.
growth and survival of CD4+ [8]; and a direct role of AKT
in CD8+ T cells has been reported, regulating whether their
diﬀerentiation leads them to either memory or eﬀector fate
[10]. In SLE patients, Suarez-Fueyo et al. [43] reported that
PI3 K pathway activation paralleled activated/memory T cell
accumulation. Our results show in SLE patients that AKT1
expression positively correlates with TNFSF10 (TRAIL)
expression, and TRAIL expression negatively correlates with
lymphocytes numbers. MAPK/ERK and PI3K/AKT signal-
ing pathways are activated by TRAIL [44]. Up-regulation of
TRAIL mRNA expression in PBMC from active SLE patients
was reported [45]. TRAIL-induced apoptosis by binding to
death receptors but also can enhance T cell proliferation after
TCR engagement via transducing a costimulation signal [46].
Our results show that MAPK1 gene expression also
correlates with gene expression levels of Th1-(IL-12A, T-
bet), Th2-(GATA3), and IL-10 genes. MAPK/ERK signaling
pathways integrate cytoplasmic signals to produce changes
in transcription associated with diﬀerentiation, proliferation,
and survival in multiple stages of T cell development [47–
49]. The results show a clear increase of IL-10 relative
gene expression in SLE PBMC, although IL-10 plasma
levels are not significantly augmented. Meta-analysis of
microarray data indicated that one of the biological pathways
consistently enhanced in SLE patients was the IL-10 signaling
[50]. IL-10 has been identified as one of the risk loci for SLE
in a recent genome-wide association study [51]. Despite that
no correlation of IL-10 gene expression with SLEDAI was
observed, IL-10 expression positively correlates with plasma
TNF-α (Table 8), and with expression levels of Th0-(IL-2),
Th1-(IL-12A, T-bet), Th2-(GATA3), Treg-(TGFB2, FOXP3),
pro-inflammatory IL-6, and Th17-(RORC)-cytokine related
genes, respectively. IL-10 is a key cytokine regulating
immune responses, and the absence results in spontaneous
inflammatory disorders as well as exacerbated inflammation
in T cell responses during host defense or autoimmune
inflammation (see reviews [52, 53]). IL-10 is expressed
by cells of the adaptive immune system (Th1, Th2, Treg
cells, and regulatory B cells (Bregs) and by cells of the
innate immune system (DCs, macrophages, mast cells, NK,
eosinophils, and neutrophils) [54, 55]. IL-10 provides a
highly regulated feedback loop to avoid the extremes of
excessive inflammation or chronic infections and also allow
a protective response to pathogens [54]. In mice, Saraiva
et al. [56] reported that development of IL-10-producing
Th1 cells required high TCR ligation, sustained ERK1 and
ERK2 MAPKs phosphorylation, and IL-12-induced STAT4
activation, indicating that ERK1 and ERK2 activation was
a common pathway required for the production of IL-10
by Th1, Th2, and Th17 cell subsets. Regulation of IL-10
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Table 6: Spearman’s rank correlations found between MAPK1,
AKT1, and Th-transcription factors gene expressions in SLE
patients.
SLE (n = 13)
Gene AKT1 T-bet STAT4 GATA3 RORC FOXP3
MAPK1
r 0.9188 0.5659 0.5609 0.6154
P <0.0001 0.0438 0.0463 0.0252
AKT1
r 1 0.6300
P 0.0210
T-bet
r 1 0.7912 0.9231 0.8958 0.9066
P 0.0013 <0.0001 <0.0001 0.0004
STAT4
r 1 0.7308 0.7253 0.5659
P 0.0045 0.005 0.0438
GATA3
r 1 0.9066 0.9066
P <0.0001 <0.0001
RORC
r 1 0.7802
P 0.0017
Significant Spearman’s rank correlations coeﬃcients are indicated.
Significance levels set at P values <0.05.
expression in mouse NK cells reported by Grant et al. [57]
indicated that like IFN-γ, IL-10 expression was induced by
IL-2 and IL-12 stimulation. Cytokines like TGF-β and IL-6
are also important regulators of IL10-producing cells [58].
It has been reported by Avagyan et al. [59] that TGF-β2
specifically enhanced signaling by the hematopoietic growth
factor fms-related tyrosine kinase (FLT)-3 in hematopoietic
stem cells. In activated human T cells, Astier et al. [60]
documented that FLT3 growth factor was acting as a negative
regulator of IL-10 levels. Furthermore, a relevant role of
IL-10 and TNF-α genotypes in SLE has been reported
[61], and IL-10 cytokine inhibits transcription elongation
of the human TNF gene in primary macrophages [62]. Our
results also show that IL-10 gene expression in SLE patients
correlates with CD38 (activation, maturation, and traﬃcking
marker) gene expression; CD38 expression correlates with
AKT1 expression. In human T and B cells, upon receptor
stimulation CD38 leads to PKB/AKT and ERK activation
[63, 64]. Moreover, in a kinase-dead mutant of PI3Kp110δ
mice, Patton et al. [65] reported that PI3Kp110δ kinase
regulates expression of CD38 on Treg. Furthermore, Blair
et al. [66] documented that CD19+CD24hiCD38hi-B cells
exhibit regulatory capacity in healthy individuals while the
same B cells from SLE patients produced less IL-10 and
lacked the suppressive capacity.
Our data show a clear increase in FOXP3-(Treg) gene
expression levels in SLE patients and positively correlate with
IL-10 gene expression. Recent reports provided new data
about the mechanisms linking IL-10 and Treg cells by
Table 7: Spearman’s rank correlations found between gene
expressions of AKT1, MAPK1, FOXP3, cytokines, IL-10, and Th-
transcription factors.
SLE (n=13)
Gene AKT1 MAPK1 FOXP3 RORC GATA3 T-bet
IL-2
r 0.7692
P 0.0021
IL-5
r 0.6970 0.7895 0.6575
P 0.0081 0.0013 0.0106
IL-6
r 0.6484
P 0.0165
IL-10
r 0.5549 0.8022 0.6923 0.7143 0.5604
P 0.0490 0.0010 0.0087 0.0061 0.0463
IL-12A
r 0.5942 0.9051
P 0.0322 <0.0001
IFN-γ
r 0.6703
P 0.0122
TNFSF10
r 0.6556
P 0.0150
TGFB2
r 0.6584 0.6960 0.6990
P 0.0144 0.0082 0.0082
Significant Spearman’s rank correlations coeﬃcients are indicated.
Significance levels set at P values <0.05.
demonstrating that IL-10 directly signals in Th17 and Treg
cells to maintain control of Th17 cell-mediated inflamma-
tion [67, 68]. In addition, IL-10-producing B cells, also
known as regulatory B cells (Bregs), play a key role in
controlling autoimmunity. Carter et al. [55] reported that
chimeric mice specifically lacking IL-10-producing B cells
developed an exacerbated arthritis compared with chimeric
wild-type B cell mice. Moreover, a significant decrease in the
absolute numbers of FOXP3 regulatory T cells (Tregs), in
their expression level of FOXP3 and a marked increase in
inflammatory Th1 and Th17 cells were detected in chimeric
mice lacking IL-10-producing B cells compared with WT B-
cell mice [55].
How Treg cell function and FOXP3 expression are
regulated is an important question under intensive investi-
gation [69]. Barreto et al. [70] reported a promoter poly-
morphism in FOXP3 gene associated with SLE. In SLE
patients, increased gene expression of FOXP3 compared to
healthy controls has been reported [71]. In SLE patients,
several reports indicated that increased proportions of
CD4+CD25−Foxp3+ T cells were correlated with the clinical
disease activity and the daily cortisone dose [72, 73]. In our
study, we cannot exclude that treatments received by SLE
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Table 8: Spearman’s rank correlation test.
SLE (n = 13)
CRPc Nd Age C4c Lf CD38e ZAP70e CCR6e
Cytokinesa Genee
IL-1β IL-2
r 0.5944 r 0.6658
P 0.0415 P 0.0130
IL-2 IL-10
r 0.6671 r 0.6107 0.5915
P 0.0178 P 0.0266 0.0332
IL-6 IL-12A
r 0.6160 r 0.6419
P 0.0329 P 0.0180
IL-10 TGFB2
r 0.6690 r 0.5909
P 0.0174 P 0.0335
IL-13 TNFSF10
r 0.8629 r −0.5750
P 0.0003 P 0.0398
IFN-γ TNF-α
r 0.7261 r 0.6740
P 0.0075 P 0.0115
TNF-α AKT1
r 0.6834 r 0.6061
P 0.0143 P 0.0281
GATA-3
r 0.6190
P 0.0241
STAT4
r 0.7836 0.5659
P 0.0026 0.0438
Calprotectinb CCR6
r 0.6593 r 0.7343
P 0.0142 P 0.0065
a
Plasma Cytokines (pg/mL).
bCalprotectin plasma levels (ng/mL).
cn = 12.
dN: Neutrophils.
eGene: Gene expression, as indicated in legend of Figure 1.
fL: Lymphocytes.
Significant Spearman’s rank correlations coeﬃcients are indicated.
Significance levels set at P values <0.05.
patients could have an eﬀect on the results. Although, a
recent report from Sbiera et al. [74] documented that short-
term glucocorticoid therapy in vivo either in immunologi-
cally uncompromised humans or in mice did not induce an
increased in the frequency of circulating Treg cells.
Balance between FOXP3 and RORC function has been
postulated that determines CD4+T cell fate and the type of
immune response that will be generated [75]. Th17 and Treg
seem to be closely linked [33, 76]. Several studies reported in
active SLE patients an imbalance between Treg and Th17 cells
[77–79]. Moreover new information has been reported about
the interplay between Tregs and Th2 cells [80]. Wang et al.
[81] demonstrated an essential role for GATA3, in controlling
Treg cell homeostasis by stabilizing expression of FOXP3.
Our results show an increased balance of both FOXP3
(Treg)/RORC (Th17) and FOXP3 (Treg)/GATA3 (Th2) gene
expression ratios in PBMC from SLE patients with inactive or
middle disease, suggesting a trend towards Treg polarization.
In addition, our results show no significant increases com-
pared with controls in the T-bet (Th1)/RORC (Th17), T-bet
(Th1)/GATA3 (Th2), and RORC (Th17)/GATA3 (Th2) gene
expression ratios in PBMC from SLE patients. Our data also
show a low relative gene expression levels of Th17-associated
CCR6 (is a trait of tissue-homing eﬀector T cells lymphocyte
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traﬃcking) in PBMC from the SLE patients with inactive or
middle disease. CCR6 expression on CD4+T cells has been
considered as a marker of disease activity in SLE patients
[82]. In addition, Sallusto et al. [83] reported that following
TCR stimulation, human memory/eﬀector T cells down-
regulate receptors for constitutive chemokines (including
CCR6). They suggested that following TCR stimulation
eﬀector/memory T cells transiently acquire responsiveness to
constitutive chemokines. As a result, T cells that are activated
in tissues may either recirculate to draining lymph nodes or
migrate to nearby sites of organized ectopic lymphoid tissues
[83].
Several studies have shown a trend towards increased
Th17 cells and Th17/Th1 ratio in SLE patients with active
disease [82, 84]. Furthermore, reports on function and num-
bers and Treg cells in SLE have been contradictory (reviews
[75, 85]), suggesting that not all FOXP3+T cells in SLE have
protective suppressive activity. Plasticity of CD4+FOXP3+T
cells has been documented [34, 86], and it has been
reported that conversion of human FOXP3+ Tregs into IL-
17-producing cells can be enhanced in the context of an
inflammatory cytokine milieu (IL-1β and IL-6) [75, 76, 86,
87].
Tregs presented core suppressive mechanisms driven by
FOXP3. Nevertheless they are also able to adapt in response
to stimuli by homing to sites of inflammation and exerting
suppressive functions. It has been reported that Treg are able
to express other transcription factors normally associated
with other Th cell subtypes in order to better control
immunopathology (see review [34]). In our study, plasma
levels of proinflammatory cytokines IL-1β, IL-12(p70), IFN-
γ, and IL-6 are significantly augmented in SLE patients
with inactive or middle disease compared with controls. In
SLE it has been suggested that aberrant control of immune
cell responses to inflammatory cytokines may disrupt the
delicate balance between immunity and self-reactivity [2,
3, 88]. IL-6 has been studied in human SLE, and IL-6 was
found to reflect disease activity [19, 89–93]. IL-6 contributes
to host defence against acute environmental stress, and
continuous deregulated IL-6 production plays a significant
pathological role in systemic autoimmune diseases [94]. IL-
6 has been known to have a key role in the maturation of
B cells, as well to be one of the members of cytokines
that drives the acute inflammatory response together with
TNF-alpha and IL-1 [94]. Additionally, plasma IL-5 (Th2)
was significantly augmented in SLE patients versus controls.
IL-5 is produced by natural helper cells and is involved
in antibody production [95, 96]. IL-5 is a critical growth
factor for B1 cells present in the peritoneal cavity and
plays an important role in innate-type immune responses
by producing natural antibodies [97–99]. Wen et al. [100]
reported that deregulated, continuous high expression of
IL-5 in SLE-prone mice may directly or indirectly mediate
a skewed signaling of proliferation/diﬀerentiation of self-
antigen-activated B1 cells, leading to suppression of autoim-
mune disease, but instead of aberrant expansion of B1
cells, giving rise to B-cell chronic lymphocytic leukaemia
(B-CLL). Moreover, despite no correlation with SLEDAI,
our results indicate that Th17-(IL-1β, IL-6), Th0-(IL-2),
Th1-(IFN-γ, TNF-α), Th2-(IL-13), and IL-10 plasma
cytokines are positively correlated with the inflammation
mediator CRP. During inflammation altered cytokine levels
are produced by diﬀerent cell populations in an interdepen-
dent mode [101]. These results are consistent with those of
other studies [102, 103].
Moreover, our results show amoderate increase of ZAP70
tyrosine kinase gene expression in SLE’s PBMC and ZAP70
correlate with gene expressions levels of TNF-α (Table 8).
Syk and ZAP-70 kinases also associated diﬀerently with key
molecules involved in cytoskeletal and calcium signaling in
SLE T cells [15]. In human mature T cells, Meinl et al.
[104] demonstrated a key role of ZAP70 in CD2-mediated
phosphorylation of CD3zeta chain of TCR, in Ca2+ influx,
proliferation, and production of IFN-γ and TNF-α.
Furthermore our data show that increased inflamma-
tion mediator S100A8/S100A9-Calprotectin plasma levels in
SLE patients positively correlate with neutrophils numbers.
S100A8/S100A9-Calprotectin is expressed by neutrophils,
monocytes, activated macrophages [105] and released in
Neutrophil Extracellular Traps [106]. These results also
accord with our earlier observations [29], which showed
in SLE PBMCs that increased S100A9 levels, correlated
positively with the abnormal presence of low-density granu-
locytes detected by flow cytometry in the mononuclear cells.
Despite the fact that the study has been performed in a
small number of patients, the results and the positive correla-
tions found suggest biological functions and associations that
need to be further confirmed in a larger cohort of patients.
5. Conclusions
SLE patients with inactive or mild disease presented a sys-
temic immunoinflammatory activity with augmented AKT1
and MAPK1 gene expressions, plasma proinflammatory
cytokines, and Calprotectin, together with increased gene
expression of Treg-related genes, suggesting an ongoing
regulatory feedback opposing the inflammatory activity.
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